Summary
Cytokines are now commonly used in the treatment of many conditions, especially cancer, haematological malignancies and chronic viral hepatitis. With some of these cytokines, clinical induction and/or exacerbation of autoimmune manifestations have been observed. This has been the case with interferon-α and interferon-γ, interleukin-2 and some colony-stimulating factors. All known biological and clinical autoimmune features have been observed but thyroid abnormalities have been particularly frequent. Some of these manifestations appear to be related to the effect of these exogenous cytokines on the T helper cell (TH) 1/TH2-cytokine balance and the regulatory properties of these cells. Patients with a history of underlying autoimmune disease or baseline serological abnormalities should be monitored for autoimmunity when treated with certain TH1 or TH2-inducing cytokines.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fujita S, Puri RK, Yu ZX, et al. An ultrastructural study of in vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin 2. Cancer 1991; 68 (10): 2169–74
Haddad J, Deny P, Munz Gotheil C, et al. Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339 (8789): 321–3
Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327 (21): 1490–5
Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991; 34 (12): 1606–10
Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132 (5): 587–93
Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant inter-leukin-2 therapy in advanced malignancies. Acta Endocrinol 1993; 129 (1): 31–8
Garcia Buey L, Garcia Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108 (6): 1770–7
Miossec P. Acting on the cytokine balance to control autoimmunity and chronic inflammation. Eur Cytokine Netw 1993; 4: 245–51
Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73
Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; 12: 256–7
Chomarat P, Rissoan M-C, Banchereau J, et al. Interferon γ inhibits interleukin-10 production by monocytes. J Exp Med 1993; 177:523–7
Kapsenberg ML, Wierenga EA, Van Der Heijden FL, et al. Atopic dermatitis and CD4+ atopen-specific TH2 lymphocytes. Eur J Dermatol 1992; 8: 601–7
Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87–99
Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277–9
Hess AD, Jones RJ, Morris LE, et al. Autologous graft-versus-host disease: a novel approach for antitumor immunotherapy. Hum Immunol 1992; 34 (3): 219–24
Daynes RA, Araneo BA, Dowell TA, et al. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1990; 171: 979–96
Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88: 346–50
Gonzalo JA, Cuende E, Ales Martinez JE, et al. Interleukin-2: a possible trigger for autoimmunity. Int Arch Allergy Immunol 1992; 97 (4): 251–7
Kroemer G, Martinez C. Interleukin-2, a pro-autoimmune lymphokine that interferes with post-deletional tolerance. Semin Immunol 1992; 4 (3): 167–79
Nathan CF. Coordinate actions of growth factors in monocytes/ macrophages. In: Sporn MB, Roberts AB, editors. Peptide growth factors and their receptors II. Berlin: Springer-Verlag, 1990: 427–53
Becker JC, Dummer R, Schwinn A, et al. Circulating intercellular adhesion molecule 1 in melanoma patients: induction by interleukin 2 therapy. J Immunother 1992; 12 (2): 147–50
Baars JW, de Boer JP, Wagstaff J, et al. Interleukin 2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia. Br J Haematol 1992; 82 (2): 295–301
Punt KC, Jansen RL, De Mulder PH, et al. Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study. J Immunother 1992; 12 (4): 277–84
Huynh HK, Oger J, Dorovini Zis K. Interferon-beta down-regulates interferon-gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells. J Neuroimmunol 1995; 60 (1–2): 63–73
Brod SA, Marshall GD Jr, Henninger EM, et al. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 1996; 46 (6): 1633–8
Realdi G, Fattovich G, Pastore G, et al. Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. J Hepatol 1990; 11 Suppl. 1: S129–32
Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24 (1): 38–47
Hirashima N, Mizokami M, Orito E, et al. Chronic hepatitis C complicated by Coombs-negative hemolytic anemia during interferon treatment. Intern Med 1994; 33 (5): 300–2
Radin AI, Buckley P, Duffy TP. Interferon therapy for agnogenic myeloid metaplasia complicated by immune hemolytic anemia. Hematol Pathol 1991; 5 (2): 83–8
McSweeney EN, Giles FJ, Worman CP, et al. Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol 1993; 85 (1): 77–83
Siciliano R, Trovato BA, Seminara G, et al. Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Ann Ital Med Int 1995; 10 (3): 193–4
Shrestha R, McKinley C, Bilir BM, et al. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995; 90 (7): 1146–7
Murakami CS, Zeller K, Bodenheimer HC Jr, et al. Idiopathic thrombocytopenic purpura during interferon alpha 2B treatment for chronic hepatitis. Am J Gastroenterol 1994; 89 (12): 2244–5
Durand JM, Lefevre P, Telle H, et al. Thrombocytopenic purpura and hepatitis C virus infection [letter]. Haematologica 1993; 78 (2): 135
Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol 1994; 21 (2): 350–2
Wandl UB, Nagel Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65 (1): 70–4
Bojic I, Lilic D, Radojcic C, et al. Deterioration of mixed cryoglobulinemia during treatment with interferon alpha 2a. J Gastroenterol 1994; 29 (3): 369–71
Harle JR, Disdier P, Pelletier J, et al. Dramatic worsening of hepatitis C virus-related cryoglobulinemia subsequent to treatment with interferon alfa [letter]. JAMA 1995; 274 (2): 126
Scheibenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994; 30A (8): 1209–11
Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88 (10): 1756–8
Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma: results of immunohistologic investigations. Arch Dermatol 1990; 126(3): 351–5
Fattovich G, Betterle C, Brollo L, et al. Autoantibodies during alpha interferon therapy for chronic hepatitis B. J Med Virol 1991; 34 (2): 132–5
Fattovich G, Betterle C, Brollo L, et al. Induction of autoantibodies during alpha interferon treatment in chronic hepatitis B. Arch Virol Suppl 1992; (4): 291–3
Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1995; 132 (3): 474–8
Wandl UB, Kloke O, Nagel Hiemke M, et al. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pre-treated patients with Ph-positive chronic myelogenous leukaemia. Br J Haematol 1992; 81 (4): 516–9
Silvestri F, Virgolini L, Mazzolini A, et al. Development of autoimmune thyroid diseases during long-term treatment of hematological malignancies with alpha-interferons. Haematologica 1994; 79 (4): 367–70
Nagayama Y, Ohta K, Tsuruta M, et al. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 1994; 41 (5): 565–72
Vallisa D, Cavanna L, Berte R, et al. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 1995; 93 (1): 31–5
Lisker Melman M, Di Bisceglie AM, Usala SJ, et al. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102 (6): 2155–60
Lim SH, Callaghan T, Goldstone AH. Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion. Acta Haematol 1991; 85 (1): 49–50
Chung YH, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am J Gastroenterol 1993; 88 (2): 244–7
Monig H, Hauschild A, Lange S, et al. Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma. Clin Investig 1994; 72 (12): 975–8
Gisslinger H, Gilly B, Woloszczuk W, et al. Thyroid autoimmunity and hypothyroidism during long term treatment with recombinant interferon alpha. Clin Exp Immunol 1992; 90 (3): 363–7
Waguri M, Hanafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994; 23 (1): 33–6
Krug J, Fritzsch J, Aust G. Induction of insulin antibodies and insulin allergy under alpha interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus: a case report. Int Arch Allergy Immunol 1995; 106 (2): 169–72
Schilling PJ, Kurzrock R, Kantarjian H, et al. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991; 68 (7): 1536–7
Flores A, Olive A, Feliu E, et al. Systemic lupus erythematosus following interferon therapy [letter]. Br J Rheumatol 1994; 33 (8): 787
Tolaymat A, Leventhal B, Sakarcan A, et al. Systemic lupus erythematosus in a child receiving long-term interferon therapy. J Pediatr 1992; 120 (3): 429–32
Conlon KC, Urba WJ, Smith JWD, et al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-inter-feron therapy. Cancer 1990; 65 (10): 2237–42
O’Connell PG, Gerber LH, Digiovanna JJ, et al. Arthritis in patients with psoriasis treated with gamma interferon. J Rheumatol 1992; 19 (1): 80–2
Cleveland MG, Mallory SB. Incomplete Reiter’s syndrome induced by systemic interferon alpha treatment. J Am Acad Dermatol 1993; 29 (5 Pt 1): 788–9
Matsuya M, Abe T, Tosaka M, et al. The first case of polymyositis associated with interferon therapy. Intern Med 1994; 33 (12): 806–8
Esteva Lorenzo FJ, Janik JE, Fenton RG, et al. Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 1995; 76 (7): 1219–23
Perez A, Perella M, Pastor E, et al. Myasthenia gravis induced by alpha interferon therapy. Am J Hematol 1995; 49 (4): 365–6
Batocchi AP, Evoli A, Servidei S, et al. Myasthenia gravis during interferon alfa therapy. Neurology 1995; 45 (2): 382–3
Piccolo G, Franciotta D, Versino M, et al. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment [letter]. J Neurol Neurosurg Psychiatry 1996; 60 (3): 348
Mase G, Zorzon M, Biasutti E, et al. Development of myasthenia gravis during interferon alpha treatment for anti HCV positive chronic hepatitis. J Neurol Neurosurg Psychiatry 1996; 60 (3): 348–9
Schwarzer A, Schulze E, Leiblein S, et al. Guillain Barré syndrome, a possible side effect of buffy coat transfusion and IFN alpha therapy in relapsed CML after bone marrow transplantation [letter]. Ann Oncol 1995; 6 (6): 617
Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha interferon. Ann Intern Med 1992; 116 (1): 51–3
Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102 (4 Pt 1): 1406–8
Marcellin P, Colin JF, Boyer N, et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha interferon [letter]. Lancet 1991; 338 (8770): 828
Czaja AJ. Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am 1994; 23 (3): 547–66
Ferri C, Longombardo G, La Civita L, et al. Hepatitis C virus, autoimmune liver disease and cryoglobulinaemic hepatitis. J Hepatol 1992; 16 (1–2): 242–3
Heintges T, Niederau C. Differentiation between autoimmune hepatitis and hepatitis C virus-related liver disease. Z Gastroenterol 1993; 31 (5): 285–8
Muratori L, Lenzi M, Cataleta M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21 (2): 199–203
Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig Dis Sci 1995; 40 (8): 1842–4
Ariad S, Song E, Cohen R, et al. Interferon-alpha induced autoimmune hepatitis in a patient with Philadelphia chromosome-positive chronic myeloid leukemia with cytogenetically normal T lymphocytes. Mol Biother 1992; 4 (3): 139–42
D’Amico E, Paroli M, Fratelli V, et al. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995; 40 (10): 2113–6
Maeda T, Onishi S, Miura T, et al. Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C. Dig Dis Sci 1995; 40 (6): 1226–30
Browett PJ, Nelson J, Tiwari S, et al. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14 (4): 641–4
Dousset B, Conti F, Houssin D, et al. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver transplant recipients. N Engl J Med 1994; 330 (16): 1160–1
Gadano AC, Mosnier JF, Durand F, et al. Alpha interferon induced rejection of a hepatitis C virus infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995; 59 (11): 1627–9
Magnone M, Holley JL, Shapiro R, et al. Interferon alpha induced acute renal allograft rejection. Transplantation 1995; 59 (7): 1068–70
Min AD, Bodenheimer HC Jr. Does interferon precipitate rejection of liver allografts? Hepatology 1995; 22 (4 Pt 1): 1333–5
Sacchi S, Kantarjian H, O’Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13 (9): 2401–7
Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab 1995; 80 (3): 922–6
Ferri C, Marzo E, Longombardo G, et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 1993; 81 (5): 1132–6
Ferri C, Marzo E, Longombardo G, et al. Alpha interferon in the treatment of mixed cryoglobulinaemia patients. Eur J Cancer 1991; 27 Suppl. 4: 81S–2S
Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676–80
Ballmer Weber BK, Dummer R, Kung E, et al. Interleukin-2 induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer 1995; 71 (1): 78–82
Ogilvie AC, Baars JW, Eerenberg AJ, et al. A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high dose interleukin-2. Br J Cancer 1994; 69 (3): 596–8
Lissoni P, Barni S, Cattaneo G, et al. Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. Int J Biol Markers 1990; 5 (4): 195–7
Gaspari AA. Autoimmunity as a complication of interleukin-2 immunotherapy: many unanswered questions [comment]. Arch Dermatol 1994; 130 (7): 894–8
Massarotti EM, Liu NY, Mier J, et al. Chronic inflammatory arthritis after treatment with high dose interleukin-2 for malignancy. Am J Med 1992; 92 (6): 693–7
Finger DR, Plotz PH, Heywood G. Myositis following treatment with high dose interleukin 2 for malignancy [letter]. J Rheumatol 1995; 22 (11): 2188
Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991; 68: 2384–90
Perez R, Padavic K, Krigel R, et al. Antierythrocyte autoanti-body formation after therapy with interleukin 2 and gamma interferon. Cancer 1991; 67 (10): 2512–7
Puduvalli VK, Sella A, Austin SG, et al. Carpal tunnel syndrome associated with interleukin 2 therapy. Cancer 1996; 77 (6): 1189–92
Dummer R, Miller K, Eilles C, et al. The skin: an immunoreactive target organ during interleukin 2 administration? Dermatologica 1991; 183 (2): 95–9
Baars JW, Wagstaff J, Hack CE, et al. Angioneurotic oedema and urticaria during therapy with interleukin 2 (IL 2). Ann Oncol 1992; 3 (3): 243–4
Baars JW, Coenen JL, Wagstaff J, et al. Lobular panniculitis after subcutaneous administration of interleukin 2 (IL-2), and its exacerbation during intravenous therapy with IL-2. Br J Cancer 1992; 66 (4): 698–9
Heinzer H, Huland E, Huland H. Adverse reaction to contrast material in a patient treated with local interleukin 2 [letter]. Am J Roentgenol 1992; 158 (6): 1407
Heywood GR, Rosenberg SA, Weber JS. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J Natl Cancer Inst 1995; 87 (12): 915–22
Zukiwski AA, David CL, Coan J, et al. Increased incidence of hypersensitivity to iodine-containing radiographie contrast media after interleukin-2 administration. Cancer 1990; 65 (7): 1521–4
Puett DW, Fuchs HA. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine-activated killer cells for renal cell carcinoma. J Rheumatol 1994; 21 (4): 752–3
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39 (3): 285–94
Kung AW, Jones BM, Lai CL. Effects of interferon-gamma therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J Clin Endocrinol Metab 1990; 71 (5): 1230–4
Bobbio Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995; 12 (2): 140–2
Sampaio EP, Moreira AL, Sarno EN, et al. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992; 175(6): 1729–37
Seitz M, Franke M, Kirchner H. Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma. Ann Rheum Dis 1988; 47: 642–4
Cannon GW, Emkey RD, Denes A, et al. Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis. J Rheumatol 1993; 20 (11): 1867–73
Myers LW, Ellison GW. The peculiar difficulties of therapeutic trials for multiple sclerosis. Neurol Clin 1990; 8 (1): 119–41
Hoshina Y, Moriuchi J, Nakamura Y, et al. CD4+ T cell mediated leukopenia of Felty’s syndrome successfully treated with granulocyte colony stimulating factor and methotrexate. Arthritis Rheum 1994; 37 (2): 298–9
de Vries EG, Willemse PH, Biesma B, et al. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy [letter]. Lancet 1991; 338 (8765): 517–8
Hayat SQ, Hearth Holmes M, Wolf RE. Flare of arthritis with successful treatment of Felty’s syndrome with granulocyte colony stimulating factor (GCSF). Clin Rheumatol 1995; 14 (2): 211–2
Kiely PD, Bruckner FE. Acute arthritis following interferon alpha therapy. Br J Rheumatol 1994; 33 (5): 502–3
Vidarsson B, Geirsson AJ, Onundarson PT. Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony stimulating factor for Felty’s syndrome. Am J Med 1995; 98 (6): 589–91
McMullin MF, Finch MB. Felty’s syndrome treated with rhG-CSF associated with flare of arthritis and skin rash. Clin Rheumatol 1995; 14 (2): 204–8
Yasuda M, Kihara T, Wada T, et al. Granulocyte colony stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty’s syndrome patient. Arthritis Rheum 1994 37 (1): 145–6
Storek J, Glaspy JA, Grody WW, et al. Adult onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis. Am J Hematol 1993; 43 (2): 139–43
Bhalla K, Ross R, Jeter E, et al. G-CSF improves granulocytopenia in Felty’s syndrome without flare-up of arthritis. Am J Hematol 1993; 42 (2): 230–1
Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115 (3): 178–83
Miossec P, Chomarat P, Dechanet J. Bypassing the antigen to control rheumatoid arthritis. Immunol Today 1996; 17: 170–3
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miossec, P. Cytokine-Induced Autoimmune Disorders. Drug-Safety 17, 93–104 (1997). https://doi.org/10.2165/00002018-199717020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199717020-00002